Bayer subsidiary BlueRock Therapeutics is evaluating digital health technologies that it hopes could support the development of its stem cell-based therapy for Parkinson’s
At the HealthTech X Digitisation of Pharma summit in London in February, pharmaphorum editor-in-chief Jonah Comstock grabbed Nigel Brokenshire, director of UK digital for Bayer, for a quick intervi
Shares in Astellas Pharma were weaker this morning on the news that the FDA has delayed its review of one of its top pipeline prospects – menopause drug fezolinetant – by
Roche is on course for a third indication for its fast-growing ophthalmic disease therapy Vabysmo, after a pair of phase 3 trials showed it was effective at improving eyes
Inato has raised $20 million in early-stage financing to support the continued development of its clinical trial marketplace, which connects sponsors with its network of t